Abstract:Background: The Bethesda System for Reporting Thyroid Cytopathology (TBSRTC) predicts the risk of malignancy for the different categories of the ultrasound-guided fine-needle aspiration biopsy (FNAB). The objective of this study is to investigate the efficiencies of the v-raf murine sarcoma viral oncogene homolog B1 (BRAF) V600E mutation test and the TBSRTC categories in distinguishing between benign and malignant thyroid nodules. Methods: In this study, 362 ultrasound-guided fine-needle aspiration (FNA) samples from 344 patients aged from 17 to 76 years old were retrospectively reviewed. The patients were classified into six groups (I-VI) according to the TBSRTC system. The amplification refractory mutation system-polymerase chain reaction (ARMS-PCR) was used to evaluate the BRAF V600E mutation level in total 362 samples. Among of the 344 patients, 128 patients (131 thyroid nodules) who underwent surgeries were followed by histopathological examination. The predictive values of the BRAF V600E mutation test and TBSRTC categories were evaluated in these 131 thyroid nodules. Results: The median ages of the patients in the TBSRTC IV-VI group were smaller than those in the TBSRTC I-III groups. The proportion of nodules over 1 cm was larger than it in the TBSRTC IV group compared to the other groups. Significant differences in BRAF V600E mutation were observed (P < .001) among these six groups. The sensitivity (89.57%) for the detection of malignant thyroid nodules, negative predictive value (NPV; 45.45%) for the detection of benign nodules, and accuracy (86.26%) for distinguishing between benign and malignant thyroid nodules increased by combining the BRAF V600E mutation test and TBSRTC system when compared with the BRAF V600E mutation test and TBSRTC system respectively. The BRAF V600E mutation test alone demonstrated the increased positive predictive value (PPV; 98.91%) and specificity (93.75%) for the detection of malignant thyroid nodules compared to the TBSRTC method (alone or in combination with the BRAF V600E method). Conclusion: In summary, significant differences in age, nodule diameter, and BRAF V600E mutation were noted among the six categories of the TBSRTC system. The combination of the BRAF V600E mutation test and TBSRTC system demonstrated increases in the NPV, sensitivity, and accuracy, while the BRAF V600E method proved superiority to the TBSRTC system with regard to the PPV and specificity.

Immunohistochemical Detection of the BRAF V600E Mutation in Melanoma Patients with Monoclonal Antibody VE1

A Validation Study for the Use Ve1 Immunohistochemical Staining in Screening for Braf Mutation in Cutaneous Malignant Melanoma

Immunohistochemistry with a mutation-specific monoclonal antibody as a screening tool for the BRAFV600E mutational status in primary cutaneous malignant melanoma

Specific Immunohistochemical Detection of the BRAF V600E Mutation in Primary and Metastatic Papillary Thyroid Carcinoma.

Validation of Immunohistochemistry for the Detection of BRAF V600E-Mutated Lung Adenocarcinomas

[Diagnostic Values of BRAF(V600E) Mutation Analysis and Bethesda System for Reporting Thyroid Cytopathology in Thyroid Nodules with TIRADS 4 and 5].

BRAF V600E Mutation and the Bethesda System for Reporting Thyroid Cytopathology of Fine-Needle Aspiration Biopsy for Distinguishing Benign from Malignant Thyroid Nodules

BRAF V600E mutation detection by immunohistochemistry in colorectal carcinoma

Biom-55. Sensitivity Of Immunohistochemistry With Braf Ve1 Antibody For Braf V600E In Primary Central Nervous System Tumors

Diagnostic value of contrast‐enhanced ultrasound combined with BRAF V600E mutation for cytologically indeterminate thyroid nodules

High sensitivity sanger sequencing detection of BRAF mutations in metastatic melanoma FFPE tissue specimens

Comparison of Molecular Methods and BRAF Immunohistochemistry (VE1 Clone) for the Detection of BRAF V600E Mutation in Papillary Thyroid Carcinoma: A Meta-Analysis

Diagnostic Value of BRAF (V600e)-Mutation Analysis in Fine-Needle Aspiration of Thyroid Nodules: a Meta-Analysis.

Clinical Significance of BRAFV600E Mutation in Circulating Tumor DNA in Chinese Patients with Melanoma

Application of immunocytochemistry and BRAF mutational analysis to direct smears of metastatic melanoma

Usefulness of BRAF VE1 immunohistochemistry in non-small cell lung cancers: a multi-institutional study by 15 pathologists in Korea

Analysis of BRAF Gene Mutation of Melanoma Derived from Different Sources

[Application of BRAF V600E Mutation-Specific Immunohistochemistry in Diagnosis of Gastrointestinal Stromal Tumors].

Factors affecting the accuracy of anti-BRAF V600E immunohistochemistry results in ameloblastomas.

A further investigation of combined mismatch repair and BRAFV600E mutation specific immunohistochemistry as a predictor of overall survival in colorectal carcinoma

Cell-SELEX-based Selection of Ssdna Aptamers for Specifically Targeting BRAF V600E-mutated Melanoma